Catatonia and neuroleptic malignant syndrome
نویسندگان
چکیده
منابع مشابه
Neuroleptic malignant syndrome and catatonia: one entity or two?
(Alder et al 1985). Both patients were heavy smokers, and tobacco smoking has been shown to interfere with the protective action of estrogens on bone mineralization. Pocock et al (1989) showed this difference in the lumbar spine and proximal femur bone densities in identical twins discordant for smoking. Polydipsia is another potential risk factor for osteoporosis, since the resulting secondary...
متن کاملCatatonia and neuroleptic malignant syndrome: two sides of a coin?
Catatonia was first described by Kahlbaum in 1874. Ever since, the concept of catatonia has been the focus of debate, a major point of discussion being its nosological status. The question rises whether it is to be considered a syndrome with a wide variety of causes and clinical signs or a distinct clinical entity. Since catatonia shares a number of symptoms with the neuroleptic malignant syndr...
متن کاملCatatonia is a risk factor for neuroleptic malignant syndrome.
Sir: I thank Drs. Carroll and Lee for their excellent comments 1 and for providing additional viewpoints through which to analyze the case reports and subtype neuroleptic malignant syndrome (NMS). They have clearly described the additional risk factors for NMS to be considered. As we focused on NMS only and the cases reviewed were already diagnosed as NMS, we did not go into the details of diff...
متن کاملOlanzapine-Induced Neuroleptic Malignant Syndrome
Neuroleptic malignant syndrome (NMS) is a rare but life-threatening idiosyncratic side effect resulting from neuroleptic drugs. NMS mainly occurs in patients treated with high-potency typical antipsychotics, but rarely caused by atypical antipsychotics. Although NMS is less common with atypical antipsychotic, but it seems that its incidence is rising due to increased administration of such drug...
متن کاملCatatonia, Neuroleptic Malignant Syndrome, and Cotard Syndrome in a 22-Year-Old Woman: A Case Report
The following case study describes a 22-year-old woman with depression and symptoms of psychosis who developed neuroleptic malignant syndrome after using Risperidone, thus requiring life support equipment and Bromocriptine, later recovering after seven days. From a psychiatric and neurological point of view, however, the persistence of catatonic syndrome and Cotard syndrome delusions was observ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Psychiatric Bulletin
سال: 2002
ISSN: 0955-6036,1472-1473
DOI: 10.1192/pb.26.5.197-a